← Back to Screener
Ainos, Inc. Common Stock (AIMD)
Price$1.95
Value ScoreD
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-15.07%
Price vs S&P 500 (4W)14.72%
VGM Score32.19
Market Capitalization$16.62M
All Metrics
Book Value / Share (Quarterly)$0.93
P/TBV (Annual)6.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-67.20%
Cash Flow / Share (Quarterly)$-0.72
Price vs S&P 500 (YTD)10.74%
Gross Margin (TTM)79.13%
Net Profit Margin (TTM)-77000.50%
EPS (TTM)$-2.90
10-Day Avg Trading Volume2.06M
EPS Excl Extra (TTM)$-2.90
Revenue Growth (5Y)44.08%
EPS (Annual)$-3.46
ROI (Annual)-79.57%
Gross Margin (Annual)82.88%
Net Profit Margin (5Y Avg)-19186.01%
Cash / Share (Quarterly)$0.47
Revenue Growth QoQ (YoY)-99.85%
ROA (Last FY)-70.77%
Revenue Growth TTM (YoY)-82.95%
EBITD / Share (TTM)$-1.67
ROE (5Y Avg)-85.21%
Operating Margin (TTM)-72397.52%
Cash Flow / Share (Annual)$-0.80
P/B Ratio2.92x
P/B Ratio (Quarterly)1.77x
Net Income / Employee (Annual)$-360,300
EV / Revenue (TTM)1523.71x
Net Interest Coverage (TTM)-19.75x
ROA (TTM)-62.29%
EV / EBITDA (TTM)9.23x
EPS Incl Extra (Annual)$-3.46
Current Ratio (Annual)1.06x
Quick Ratio (Quarterly)0.50x
3-Month Avg Trading Volume0.66M
52-Week Price Return-39.81%
Revenue / Employee (TTM)$400
Tangible BV / Share (Quarterly)$0.03
P/S Ratio (Annual)133.88x
Asset Turnover (Annual)0.01x
52-Week High$4.50
Operating Margin (5Y Avg)-18231.54%
EPS Excl Extra (Annual)$-3.46
CapEx CAGR (5Y)28.15%
Tangible BV CAGR (5Y)44.57%
26-Week Price Return-7.14%
Quick Ratio (Annual)0.78x
13-Week Price Return32.65%
Total Debt / Equity (Annual)1.45x
Current Ratio (Quarterly)0.55x
Enterprise Value$27.59M
Revenue / Share Growth (5Y)31.50%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)35.95%
Revenue / Employee (Annual)$3,000
Inventory Turnover (Annual)0.10x
Pretax Margin (Annual)-11896.11%
Cash / Share (Annual)$0.07
3-Month Return Std Dev228.52%
Gross Margin (5Y Avg)-33.82%
Net Income / Employee (TTM)$-340,100
ROE (Last FY)-195.32%
Net Interest Coverage (Annual)-18.69x
EPS Basic Excl Extra (Annual)$-3.46
P/FCF (TTM)110.82x
Receivables Turnover (TTM)329.27x
Total Debt / Equity (Quarterly)2.43x
EPS Incl Extra (TTM)$-2.90
Receivables Turnover (Annual)3104.00x
ROI (TTM)-68.39%
P/S Ratio (TTM)917.88x
Pretax Margin (5Y Avg)-19184.98%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.09
Price vs S&P 500 (52W)-64.18%
Year-to-Date Return18.90%
5-Day Price Return-16.31%
EPS Normalized (Annual)$-3.46
ROA (5Y Avg)-42.57%
Net Profit Margin (Annual)-11896.75%
Month-to-Date Return-18.07%
Cash Flow / Share (TTM)$-0.25
EBITD / Share (Annual)$-2.16
Operating Margin (Annual)-11268.05%
LT Debt / Equity (Annual)1.45x
ROI (5Y Avg)-49.22%
LT Debt / Equity (Quarterly)1.58x
EPS Basic Excl Extra (TTM)$-2.90
P/TBV (Quarterly)26.79x
P/B Ratio (Annual)1.04x
Inventory Turnover (TTM)0.02x
Pretax Margin (TTM)-76996.08%
Book Value / Share (Annual)$1.30
Price vs S&P 500 (13W)24.40%
Beta2.43x
Revenue / Share (TTM)$0.00
ROE (TTM)-160.55%
52-Week Low$1.26
vGradeD
gGradeD
mGradeD
vgmGradeD
Show chart for
Industry Peers — Computer Peripherals(21)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AIMDAinos, Inc. Common Stock | D | D | D | $1.95 |
| PANWPalo Alto Networks, Inc. Common Stock | F | B | B | $272.05 |
| FTNTFortinet, Inc. | F | B | B | $144.68 |
| LOGILogitech International SA | C | D | C | $112.93 |
| EVLVEvolv Technologies Holdings, Inc. Class A Common Stock | F | A | C | $5.91 |
| CRSRCorsair Gaming, Inc. Common Stock | B | D | C | $9.01 |
| SSYSStratasys Inc (ISRAEL) | C | F | D | $8.85 |
| MITKMitek Systems, Inc. | C | C | C | $14.89 |
| XRXXerox Holdings Corporation Common Stock | A | C | C | $3.32 |
| IMMRImmersion Corp | A | D | D | $6.37 |
| RDCMRadcom Ltd. | C | B | D | $12.32 |
About
Ainos Inc combines artificial intelligence with biotech development across two distinct platforms. Its AI division creates sensing technology that digitizes scent data for applications in robotics, manufacturing, and healthcare, while its biotech unit develops oral interferon therapeutics for rare, autoimmune, and infectious diseases. The dual-platform approach targets multiple markets in emerging sensory technology and specialized pharmaceuticals.